Jinhe Net Income Applicable To Common Shares from 2010 to 2024

002688 Stock   4.48  0.10  2.28%   
Jinhe Biotechnology's Net Income Applicable To Common Shares is increasing over the years with slightly volatile fluctuation. Overall, Net Income Applicable To Common Shares is expected to go to about 112.1 M this year. Net Income Applicable To Common Shares is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Income Applicable To Common Shares  
First Reported
2018-06-30
Previous Quarter
52.4 M
Current Value
13.7 M
Quarterly Volatility
27.6 M
 
Covid
Check Jinhe Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jinhe Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 8.6 M, Selling General Administrative of 167.5 M or Total Revenue of 1.5 B, as well as many indicators such as . Jinhe financial statements analysis is a perfect complement when working with Jinhe Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Jinhe Biotechnology Technical models . Check out the analysis of Jinhe Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jinhe Stock

Jinhe Biotechnology financial ratios help investors to determine whether Jinhe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jinhe with respect to the benefits of owning Jinhe Biotechnology security.